ERAS News

Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Shareholders to Inquire about Securities Investigation

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law Office is Investigating Claims on Your Behalf

Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Shareholders to Connect

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating

Erase.com Named to 2026 Inc. 5000 for Second Consecutive Year Ready to Announce with Confidence?

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Erasca, Inc. (ERAS) and Encourages Shareholders to Learn More About the Investigation

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Stockholders to Inquire about Securities Investigation